AI/ML Innovations Inc. Enters Binding Letter of Intent to Acquire Strategic Neural Net Healthcare Assets
AI/ML Innovations Inc. Enters Binding Letter of Intent to Acquire Strategic Neural Net Healthcare Assets
Highlights:
亮點：
- Strategic Expansion and Market Growth: AI/ML Innovations Inc. expands its portfolio by acquiring Naiad Labs Inc. Product Division.
- AI-driven Strategic Healthcare Assets: The purchase includes a proprietary "Long ECG Neural Net", reducing the reading and labeling of long ECGs from a couple of weeks to under 5 minutes.
- 戰略擴張和市場增長：AI/ML Innovations Inc.通過收購Naiad Labs Inc.產品部門擴大其產品組合。
- 人工智能驅動的戰略醫療資產：此次收購包括專有的 “長心電神經網絡”，將長心電圖的讀取和標籤從幾周縮短到不到5分鐘。
VICTORIA, BC / ACCESSWIRE / May 2, 2024 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce a significant milestone in the signing of a binding Letter of Intent (the "LOI") dated April 27, 2024 to purchase Naiad Labs' Product Division, subject to certain terms and conditions.
不列顛哥倫比亞省維多利亞州/ACCESSWIRE /2024年5月2日/ AI/ML Innovations Inc.（“AIML” 或 “公司”）（CSE: AIML）（OTCQB: AIML）（OTCQB: AIML）（FWB: 42FB）是一家致力於收購和推進滿足緊急社會需求的人工智能/機器學習技術的領先公司，很高興地宣佈簽署具有約束力的意向書（“LOVE”）是一個重要的里程碑 I”）於2024年4月27日收購Naiad Labs的產品部，但須遵守某些條款和條件。
The Acquired Assets include:
收購的資產包括：
Naiad's proprietary Long ECG Neural Net (L-ECG NN) - An accurate and efficient method to read and label long ECGs. The L-ECG NN can label an entire 48-hour long ECG file in less than 5 minutes, while conventional methods take a couple of weeks.
Naiad 專有的長心電神經網絡 (L-ECG NN)-一種讀取和標記長心電圖的準確而有效的方法。L-ECG NN 可以在不到 5 分鐘的時間內標記整個 48 小時的心電圖文件，而傳統方法則需要幾周的時間。
The Neural Network Store (NNStore) - A subscription-based online neural net store that allows device company developers and researchers to upload files for analysis by various AI systems.
神經網絡商店 (nnStore)-一種基於訂閱的在線神經網絡商店，允許設備公司的開發人員和研究人員上傳文件供各種 AI 系統分析。
Paul Duffy, CEO of AIML, added, "We are very excited by this acquisition, as we see great synergy between these newly acquired technologies and our current Follow Your Heart suite of products". Duffy continues, "Moreover, the Neural Net Store expands our reach, offering our Neural Nets as a Service to the broad and growing community of smart sensor wearables and end user applications.'"
AIML首席執行官保羅·達菲補充說：“我們對這次收購感到非常興奮，因爲我們看到了這些新收購的技術與我們目前的Follow Your Heart產品套件之間的巨大協同作用”。達菲繼續說：“此外，神經網絡商店擴大了我們的覆蓋範圍，爲廣泛且不斷增長的智能傳感器可穿戴設備和最終用戶應用程序社區提供我們的神經網絡即服務。”
The salient terms of the LOI include:
意向書的主要條款包括：
| 1. | AIML will purchase 100% of Naiad's Long ECG Neural Net, 100% of Naiad's Neural Net Store & NNaaS, and access to certain contracted services to be provided by Naiad's management and technical team on an ongoing basis under separate employment/consulting agreements (collectively, the "Assets"). | |
| 2. | AIML will issue 6,700,000 Common Shares from its Treasury to Naiad, (currently valued at $469,000), as full and final payment for the Assets. The shares will be subject to a 12-month hold period. | |
| 3. | AIML will create a new operating subsidiary which shall hold the Assets. | |
| 4. | AIML will pay a streaming royalty (the "Royalty") to Naiad for up to a 20-year period, as per the following terms: | |
| i. | a 2% Royalty which is payable on gross revenue of not less than $1,500,000 and not greater than $5,000,000 inclusive per fiscal year, if and only if such revenue is directly attributable to third-party licensing of the Long ECG Neural Net, AND | |
| ii. | a 3% Royalty which is payable on all gross revenue above $5,000,000 per fiscal year, if and only if such revenue is directly attributable to third-party licensing of the Long ECG Neural Net. | |
| iii. | AIML at its sole discretion may purchase the Royalty from Naiad at any time for $1,000,000. | |
| 5. | AIML will grant a total of 700,000 stock options for 5 years at a $0.20 exercise price to management members of Naiad, in accordance with the Corporation's Stock Option Plan. | |
| 6. | a 3% Royalty which is payable on all gross revenue above $5,000,000 per fiscal year, if and only if such revenue is directly attributable to third-party licensing of the Long ECG Neural Net. | |
| 7. | AIML at its sole discretion may purchase the Royalty from Naiad at any time for $1,000,000. | |
| i. | the Long ECG Neural Net has formally entered the US FDA approval process; AND, | |
| ii. | The Long ECG Neural Net generates gross revenue of not less than $1,000,000. | |
| 1。 | AIML將購買Naiad的長心電神經網絡的100％，Naiad神經網絡商店和NNAA的100％，以及NaaS的某些合同服務，這些服務將由Naiad的管理和技術團隊根據單獨的僱用/諮詢協議（統稱爲 “資產”）持續提供。 | |
| 2。 | AIML將從其財政部向奈亞德發行6,700,000股普通股（目前價值46.9萬美元），作爲資產的全額和最後一筆付款。這些股票將有12個月的持有期。 | |
| 3. | AIML將創建一個新的運營子公司，該子公司將持有資產。 | |
| 4。 | 根據以下條款，AIML將向Naiad支付長達20年的流媒體特許權使用費（“特許權使用費”）： | |
| 我。 | 當且僅當該收入直接歸因於長心電神經網絡的第三方許可時，每財年的總收入不少於1,500,000美元且不超過5,000,000美元（含），則應支付2％的特許權使用費，以及 | |
| ii。 | 當且僅當此類收入直接歸因於長心電神經網絡的第三方許可時，每財年總收入超過5,000,000美元即可支付3％的特許權使用費。 | |
| iii。 | AIML可隨時自行決定以100萬美元的價格從Naiad購買特許權使用費。 | |
| 5。 | 根據公司的股票期權計劃，AIML將以0.20美元的行使價向Naiad的管理成員授予總共70萬份爲期5年的股票期權。 | |
| 6。 | 當且僅當此類收入直接歸因於長心電神經網絡的第三方許可時，每財年總收入超過5,000,000美元即可支付3％的特許權使用費。 | |
| 7。 | AIML可隨時自行決定以100萬美元的價格從Naiad購買特許權使用費。 | |
| 我。 | 長心電神經網絡已正式進入美國食品藥品管理局的批准程序；而且， | |
| ii。 | 長心電神經網絡產生的總收入不少於1,000,000美元。 | |
The Assets Purchase has a non-arm's length component to it in that AIML's Interim CPO, Esmat Naikyar, is the CEO and co-Founder of Naiad Labs Inc. Mr. Naikyar is neither on the board of directors of AIML, nor will he be involved in AIML's approval process.
此次資產收購有非公平的組成部分，因爲AIML的臨時首席財務官埃斯馬特·奈克亞爾是Naiad Labs Inc.的首席執行官兼聯合創始人。奈克亞爾先生既不是AIML的董事會成員，也不會參與AIML的批准程序。
The closing of the Asset Purchase is subject to satisfactory completion of due diligence by AIML, AIML Board approval, any requisite regulatory approval, and other conditions typically set out in a purchase and sale agreement of this type. The parties are working to complete a definitive agreement based upon the terms found of LOI on or about May 30, 2024.
資產收購的完成取決於AIML令人滿意地完成盡職調查、AIML董事會批准、任何必要的監管批准以及此類買賣協議中通常規定的其他條件。雙方正在努力根據2024年5月30日左右的意向書條款完成最終協議。
No Finder's Fee will be paid in conjunction with this transaction. The Asset Purchase will not result in either a change of control or the creation of new control persons.
本次交易不會同時支付任何發現者費用。資產購買不會導致控制權的變更或新的控制人員的設立。
###
###
About AI/ML Innovations Inc.
關於 AI/ML Innovations Inc.
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".
AI/ML Innovations Inc.調整了其業務運營，以利用新興的人工智能（AI）和機器學習（ML）領域，最初的投資重點是新興的數字健康和福祉公司，這些公司利用人工智能、機器學習、雲計算和數字平台推動變革性的醫療管理解決方案和整個健康連續體的精準支持交付。通過與Health Gauge（AIML持有95.2％的股權）、Tech2Heal（高達22％的所有權，目前由AIML持有12.44％的所有權）、AI Rx Inc.（AIML持有70％的股權）以及其他計劃中的增值投資，公司繼續利用不斷擴大的增長領域，使公司所有利益相關者受益。AI/ML的股票在加拿大證券交易所交易，代碼爲 “AIML”，OTCQB風險投資市場以 “AIMLF” 的形式交易，在法蘭克福證券交易所交易的代碼爲 “42FB”。
On behalf of the Board of Directors
Tim Daniels, Executive Chairman
代表董事會
蒂姆·丹尼爾斯，執行主席
For more information about AI/ML Innovations:
有關 AI/ML 創新的更多信息:
For detailed information please see AI/ML's website or the Company's filed documents at
有關詳細信息，請訪問AI/ML的網站或公司提交的文件，網址爲
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com
欲了解更多信息，請致電 (778) 405-0882 或 info@aiml-innovations.com 與 Blake Fallis 聯繫
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
CSE及其監管服務提供商（該術語在CSE的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
For AI/ML Innovations Investors
致人工智能/機器學習創新投資者
Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at .
本新聞稿中發表的某些非基於歷史信息的陳述是前瞻性陳述，涉及大量已知和未知的風險和不確定性。本新聞稿包含與AI/ML Innovations對管理層計劃、目標和戰略（包括捍衛公司知識產權的戰略）的預期有關的明示或暗示的前瞻性陳述。這些陳述既不是承諾也不是擔保，但存在各種風險和不確定性，其中許多風險和不確定性是我們無法控制的，這可能導致實際結果與這些前瞻性陳述中設想的結果存在重大差異。提醒現有和潛在投資者不要過分依賴這些前瞻性陳述，這些陳述僅代表截至本文發佈之日。除非適用的證券法明確要求，否則AI/ML Innovations Inc. 沒有義務更新或修改本新聞稿中包含的信息，無論是由於新信息、未來事件或情況還是其他原因。有關不確定性和風險的更多信息，可以在AI/ML向證券監管機構提交的披露文件中找到，網址爲。
SOURCE: AI/ML Innovations Inc.
來源：AI/ML Innovations Inc.
譯文內容由第三人軟體翻譯。